Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On February 14, 2025, Dr. Reddy’s Laboratories announced the allotment of 20,155 equity shares at a par value of Re.1 each to eligible employees under the company’s Employee Stock Options Scheme of 2002. This move is part of the company’s ongoing efforts to incentivize and retain talent through stock-based compensation, reflecting its commitment to employee engagement and satisfaction. The issuance of these additional shares increases Dr. Reddy’s total issued share capital to 83,44,45,115 equity shares, reinforcing its financial standing and operational expansion.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company based in Hyderabad, India. The company is primarily involved in the manufacturing and marketing of a wide range of pharmaceutical products, including generic medicines, active pharmaceutical ingredients (APIs), and biologics. Its market focus spans across India and major global markets, including the United States, leveraging its capabilities in research, development, and production.
YTD Price Performance: -10.72%
Average Trading Volume: 1,744,972
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $11.77B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
